Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Entrada Therapeutics, Inc. Stock

Equities

TRDA

US29384C1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
15.74 USD -0.38% Intraday chart for Entrada Therapeutics, Inc. +1.75% +4.31%
May. 20 Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing MT
May. 16 Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing MT

Financials (USD)

Sales 2024 * 143M Sales 2025 * 33.68M Capitalization 500M
Net income 2024 * -20M Net income 2025 * -147M EV / Sales 2024 * 2.78 x
Net cash position 2024 * 104M Net cash position 2025 * 141M EV / Sales 2025 * 10.6 x
P/E ratio 2024 *
-31.9 x
P/E ratio 2025 *
-4.16 x
Employees 160
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.37%
More Fundamentals * Assessed data

Chart Entrada Therapeutics, Inc.

Dynamic Chart

Latest news about Entrada Therapeutics, Inc.

Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing MT
Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing MT
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Oppenheimer Starts Entrada Therapeutics With Outperform Rating, Price Target is $22 MT
Entrada Therapeutics Adds President Role to COO Nathan Dowden MT
Entrada Therapeutics Adds President Role to COO Nathan Dowden MT
Entrada Therapeutics Promotes Nathan J. Dowden to President CI
Sector Update: Health Care Stocks Gain Pre-Bell Wednesday MT
Entrada Therapeutics, Inc. cancelled the transaction announced on December 7, 2022 CI
Entrada Therapeutics, Inc. Announces Board Changes CI
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating MT
US Equity Markets Close Higher Wednesday Following Consumer Sentiment Data MT
More news

Latest transcript on Entrada Therapeutics, Inc.

Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 10:40 AM
More transcripts

Analyst Recommendations on Entrada Therapeutics, Inc.

Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing MT
Oppenheimer Starts Entrada Therapeutics With Outperform Rating, Price Target is $22 MT
HC Wainwright Adjusts Entrada Therapeutics' Price Target to $20 From $25, Maintains Buy Rating MT
HC Wainwright Starts Entrada Therapeutics at Buy With $25 Price Target MT
Goldman Sachs Adjusts Price Target on Entrada Therapeutics to $18 From $13, Maintains Neutral Rating MT
More recommendations

Press releases Entrada Therapeutics, Inc.

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference GL
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference AQ
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ GL
Entrada Therapeutics : Corporate Presentation PU
Entrada Therapeutics Reports First Quarter 2024 Financial Results GL
More press releases

News in other languages on Entrada Therapeutics, Inc.

Nipte winst op Wall Street
Wall Street licht hoger
Wall Street richting rode opening
More news

Quotes and Performance

1 day-0.38%
1 week+1.75%
Current month+1.75%
1 month+13.40%
3 months+25.12%
6 months+17.81%
Current year+4.31%
More quotes

Highs and lows

1 week
14.89
Extreme 14.89
16.47
1 month
13.82
Extreme 13.8171
16.47
Current year
11.35
Extreme 11.35
17.26
1 year
10.75
Extreme 10.7501
18.44
3 years
5.12
Extreme 5.12
36.85
5 years
5.12
Extreme 5.12
36.85
10 years
5.12
Extreme 5.12
36.85
More quotes

Managers and Directors - Entrada Therapeutics, Inc.

Managers TitleAgeSince
Dipal Doshi CEO
 Chief Executive Officer 48 17-07-31
Kory Wentworth DFI
 Director of Finance/CFO 45 20-10-31
Nathan Dowden PSD
 President 54 19-11-03
Members of the board TitleAgeSince
Peter Kim BRD
 Director/Board Member 65 20-11-30
Mary Thistle BRD
 Director/Board Member 64 21-05-03
Gina Chapman BRD
 Director/Board Member 57 23-08-31
More insiders

ETFs positioned on Entrada Therapeutics, Inc.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 32 M€ +4.30% -
More ETFs positioned on Entrada Therapeutics, Inc.

Quotes

Date Price Change Volume
24-06-07 15.74 -0.38% 48,059
24-06-06 15.8 -3.54% 41,610
24-06-05 16.38 +7.06% 88,145
24-06-04 15.3 -2.55% 94,386
24-06-03 15.7 +1.49% 93,037

Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT

More quotes

Company Profile

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Sector
Biotechnology & Medical Research
Calendar
2024-06-10 - Goldman Sachs Global Healthcare Conference - Fireside Chat
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Ratings for Entrada Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.74 USD
Average target price
22.86 USD
Spread / Average Target
+45.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENTRADA THERAPEUTICS, INC. Stock Entrada Therapeutics, Inc.
+4.31% 500M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.21B
ARGENX SE Stock argenx SE
+3.23% 22.78B
GENMAB A/S Stock Genmab A/S
-10.44% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. TRDA Stock